For how we live.
In 1,448 pregnancies, lower early placental growth factor was linked to more preterm births — yet adding it to a prediction model lifted accuracy only from 0.59 to 0.68.
A phase 1/2 trial gave mosunetuzumab plus polatuzumab to 101 older, unfit or frail people with untreated large B-cell lymphoma. The end-of-treatment response rate was 61.4%, with a complete response in 56.4%.
In a Canadian cohort of 228 women with HIV, antibody titres matched those of women without HIV and cervical precancer was not recorded — but protection tracked with viral suppression.
The agency is describing the trial design it is weighing for ibogaine, a psychedelic with serious cardiac risks, as HHS funds the first federal studies in opioid use disorder and PTSD. Comments close 20 November.
A final order codifies a new Class II category for systems that destroy soft tissue with sound rather than heat, built on HistoSonics Edison System. It becomes a predicate other makers can clear against.
Across 10 US children's hospitals and 697 patients, reoperation for recurrent twisting was rare either way — but laparoscopic repair carried lower odds of surgery for later bowel obstruction.
A single-arm phase 2 trial added glofitamab to pola-R-CHP in 41 people with newly diagnosed B-cell lymphoma. The best complete-response rate was 95%, cytokine release stayed grade 1, and no neurotoxicity was reported.
A nationwide Brazilian cohort of 4.1 million children found that babies exposed to Zika in the womb but without congenital Zika syndrome had the same pneumonia-hospitalisation risk as unexposed children.
A first-of-its-kind report from Uzbekistan puts the case-fatality rate at 8.3%. The one sign that predicted death was present in just 3.1% of patients — a warning against waiting for it.
Genomic sequencing identified Haemophilus ducreyi — a bacterium known for a sexually transmitted infection — behind roughly 403 cases in children. Of 156 swabs tested, 61.5% were positive; no yaws was found.
Nearly a third of 68 sampled cases carried the mutation that blocks first-line antibiotics — and the resistant strain hit infants under six months hardest, during an outbreak that reached 4,976 cases and 76 deaths.
A draft NIH policy out for comment would require researchers to share plain-language summary results with clinical research participants for all NIH-supported studies, unless justifiably not appropriate.
HRSA has finalised eligibility guidelines for its Living Organ Donation Reimbursement Program under the HOLD Act, which bars considering the recipient's income. Eligibility now turns on the donor's own income.
A hybrid public meeting on 26 October will discuss proposed BsUFA IV recommendations. The fees that fund FDA review of biosimilar applications expire in September 2027 and need new legislation to continue.
An FDA advisory committee will meet on 30 October to review Sydnexis's atropine sulfate 0.01% eye drops, proposed to slow myopia progression in children aged 3 and older. The public docket closes 29 October.
A Toronto cohort reports that an eight-day antiviral protocol prevented or cleared hepatitis C in all 116 recipients of organs from infected donors, with survival matching recipients of uninfected organs.
In the Nordic SWEDEGRAFT trial, the no-touch vein-harvesting technique left the rate of death, heart attack, or repeat procedures at 19.8% versus 20.4% through seven years — a difference indistinguishable from chance.
In the industry-funded evERA trial, giredestrant plus everolimus delayed progression of ER-positive breast cancer — but the clearest benefit was in ESR1-mutated tumours, and the endpoint was a surrogate, not survival.
Thirteen years on, the independent DiAPREV-IT trial still shows no overall effect from GAD-alum. A 27-child genetic subgroup saw onset delayed — but the other subgroup got worse.
Ketamine cuts suicidal thinking fast but briefly. A 50-person trial gave low-dose buprenorphine afterward and saw the effect hold — an early, single-centre result in a high-risk group.
A Global Burden of Disease 2023 analysis of 31 countries finds the burden climbing, peaking in early adolescence and heavier in women, with population growth the single biggest driver.
There is no approved drug for methamphetamine use disorder. In 339 patients treated in ordinary clinics, a generic antidepressant cut use by about two days a month more than placebo, with more dropouts from side-effects.
In LatAm-FINGERS, 1,065 at-risk older adults across 11 countries did better on cognitive tests with structured coaching than with flexible health advice over two years. The gap was small.
A randomised trial enrolled 3,259 underserved people referred for lung cancer screening. Adding free medication to standard advice did not raise quit rates; adding financial incentives roughly doubled them — to 8.8%.
The UV-free TransVitD patch raised vitamin D in animals and lab-grown skin. In a randomised trial of 108 volunteers it was safe but did not lift blood levels beyond what a small oral dose would.
AbbVie's once-daily pill cleared the FDA on 25 September as a new molecular entity. Across three phase 3 TEMPO trials it beat placebo in early Parkinson's and as an add-on to levodopa.
In the phase 3 SYNCHRONIZE-2 trial, the glucagon/GLP-1 dual agonist beat placebo on weight over 76 weeks. The effect was solid but smaller than the class leaders manage, and the maker funded it.
A meta-analysis of 10 randomised trials found ultra-processed diets raised weight and eating rate, yet the effect on how much people ate mostly disappeared when diets were not more energy-dense.
Ginger's strongest evidence is unglamorous: it eases nausea in pregnancy and during chemotherapy, and modestly relieves osteoarthritis pain. The trials are small and the quality is moderate at best.
Garlic supplements modestly lower blood pressure in hypertensive people, and may nudge cholesterol down a little. The cold-prevention evidence rests on a single trial, and no study shows garlic prevents heart attacks.
Beetroot juice really does lower blood pressure — the effect is one of the better-documented in food science, driven by dietary nitrate. But most trials are short and small, and no study shows it prevents heart attacks.
Sleeping apart is increasingly common and can genuinely cut disturbance. But the lab evidence is double-edged: sharing a bed measures as slightly worse sleep yet feels better, and may even boost REM.
Probably not ideal. Even moderate light during sleep measurably raises night-time heart rate and next-morning insulin resistance, and in one large study women who slept with a light or TV on gained more weight.
A warm bedroom measurably degrades sleep, and the best-studied comfortable band sits at roughly 20–25°C. The effect is real but personal, and heat matters more than most people assume.
Knowing you are dreaming and sometimes steering it is real and surprisingly common, and it can be trained. But deliberately inducing it may carry a mental-health cost for some people.
In the MONEAD cohort, six-year-olds whose mothers breastfed while taking antiseizure medicines scored no worse on language or adaptive behaviour — and longer breastfeeding tracked with slightly better scores.
A post hoc analysis of the BAMBINI trial asked whether losing too much weight could backfire on fertility in PCOS. It did not: every degree of weight loss was linked to a better chance of ovulating.
There has been no reliable way to prevent pre-eclampsia at term. PREVENT-PE screened over 8,000 women late in pregnancy and offered earlier birth to those at highest risk — and pre-eclampsia fell by nearly a third.
Injecting one sperm into each egg was meant for severe male-factor cases, yet clinics now use it widely. Pooling six randomised trials found no live-birth advantage over standard IVF when sperm is not the problem.
In the French GETUG AFU 18 trial an 80 Gy dose beat the standard 70 Gy on 10-year progression-free survival (83.6% vs 72.2%), but the advantage at the prespecified 5-year mark was far smaller.
An analysis of 50 top-selling 'T booster' products found only 24.8% contained an ingredient with data showing it raises testosterone — and 10.1% contained something shown to lower it. Two herbs are partial exceptions.
Urinary infections in men were long treated as automatically complicated. A randomised trial found seven days of antibiotics non-inferior to fourteen, and guidelines say not to treat urine that causes no symptoms.
Men who carry a BRCA2 mutation develop prostate cancer earlier and in more aggressive forms. Trial evidence now supports offering them PSA screening from 40; the case for BRCA1 carriers is weaker.
A population-linked Australian cohort followed children to school entry after antenatal metformin. The adjusted relative risk of developmental vulnerability was 0.97 — no different from unexposed children.
In a 366-child phase 2b trial, the live attenuated nasal vaccine BPZE1 raised the mucosal antibody current shots miss, and did not blunt a co-given Tdap. The maker funded the study.
The LEAP trial found that feeding peanut to high-risk babies from infancy cut peanut allergy at age five from 13.7% to 1.9%. A follow-up showed the protection held — but high-risk infants should be assessed first.
A Cochrane review of six trials finds honey modestly eases cough in children over one, and does as well as common syrup ingredients — while regulators say those syrups do not shorten a cold. Never give honey under one.
Long static stretches before training briefly weaken strength and power, and stretching does not prevent soreness or reliably cut injury. Save static stretching for after, or for flexibility itself.
The muscle-building literature converges on roughly 1.6 grams of protein per kilogram of bodyweight a day, with gains flattening above that — a target well clear of the deficiency floor most official figures quote.
No. When sets are pushed close to failure, light and heavy weights build muscle about equally. The one thing heavier loads reliably win is maximal strength.
The whole scare traces to one 2009 study that measured a hormone, not hair. In 2025, the first trial to actually assess hair follicles found no difference between creatine and placebo.
Visceral fat packed around the organs tends to be shed preferentially with modest weight loss. What lingers is subcutaneous fat — and you cannot choose where it comes off, which is what makes the belly feel stubborn.
A short walk after eating blunts the post-meal blood-sugar spike. Trials in people with type 2 diabetes and in healthy adults agree, and light walking beats standing, which beats sitting still.
Sea moss is sold as a 92-mineral cure-all, but no human trial shows it delivers those benefits — and because seaweed's iodine content is wildly variable, the documented risk falls on the thyroid.
Two blinded randomised trials found magnetic wrist straps and copper bracelets worked no better than dummy versions for arthritis pain. The reported relief looks like a placebo effect.
As blood stem cells age, mutant clones take over. By the eighth decade this shows up in about one person in ten — and it tracks with higher mortality and heart disease.
Finnish cohorts link regular sauna bathing to lower cardiovascular and all-cause mortality, with a dose-response. But these are observational studies, and no randomised trial has tested sauna against death.
Losing the ability to walk is a turning point in later life. In a large randomised trial, structured activity cut the rate of major mobility disability — evidence that movement protects independence, read honestly.
Failing mitochondria are one of ageing's core hallmarks, and human trials of mitochondria-targeted compounds show flickers of benefit — but the strongest endpoints keep coming back null.
In UK Biobank participants tracked with wrist light sensors, high nighttime light exposure was tied to thickened, weaker heart muscle and 24–33% higher risks of heart attack, stroke and heart failure.
Exposure is real and universal. One human study links plastics in artery plaque to worse outcomes. No causal harm is established, and the measurements are still maturing.
A five-year panel study found sales of mental-disorder medicines rose 144% in a cyclone's landfall year and 173% the next in coastal districts, with no measurable effect further inland.
A tyre-wear chemical that kills coho salmon at trace levels is now measured in most people's urine. What that means for human health is only beginning to be studied.
Computer-aided detection lifts polyp pickup in ordinary screening. In 757 patients having surveillance for an inherited cancer syndrome, a randomised trial could not show the same gain.
Rejoyn, the first prescription digital therapeutic cleared for major depression, beat a sham app on a backup analysis. Its pre-specified primary endpoint fell just short of significance.
A January 2025 draft guidance lays out the documentation the agency expects across an AI device's whole life, including bias checks across demographic groups and postmarket monitoring. It is not yet binding.
Wrist trackers infer light, deep and REM sleep from movement and pulse. Two validation studies find they track total sleep passably but each misjudges the stage breakdown its own way.
